1Downhole Monitoring Solutions

Medical Instrumentation

2

Forward Looking Statements

This corporate presentation contains forward-looking

statements, which reflect the Company’s current expectations

regarding future events. The forward-looking statements involve

risks and uncertainties. Actual events could differ materially

from those projected herein and depend on a number of factors,

including the successful and timely completion and the

commercialization of the products herein. The reader of this

document is forewarned concerning the inherent variability and

risk associated in terms of strategies or deliverables stated

herein by the Company and is cautioned prior to considering

these forward-looking statements. The Company disclaims any

obligation to update these forward-looking statements.

Listing TSX:V

Symbol OPS

Shares / diluted 59 M/69 M

Working Cap(Feb 17, 2014)

13 M

Revenue 2013 $7.5 M

3

US & Canadian Institutions

Significant Ownership by Management & Directors 23%

4

Business OverviewOpsens develops, manufactures and installs systems to measure a number of parameters, including pressure and temperature, using fiber optic sensing technologies.

Initially developed product for

Japanese medical supplier,

leveraging the Company’s fiber optic

technology

Products in Development

FFR Optical Guidewire

First regulatory filing

January 2014 (completed)

Projected FFR Market Size: US$1B+

Medical InstrumentationFractional Flow Reserve (FFR)

Operating business unit in Alberta

providing critical pressure and temp.

measurements in thermal operations

(ex. SAGD) since 2008

Flagship Product - Commercialized

OPP-W fibre optic pressure/temp sensor

In Development

OPP-G high pressure sensor

Industry Annual Capex in 2014: ~C$25B*

Downhole MonitoringOil and Gas Industry

* Source: Canadian Association of Petroleum Producers: Estimated Industry Annual Capex Spending for 2014

Platform Technology with a Focus on Large Growing Markets

5

Investment Highlights

Platform technology focused on markets with attractive growth opportunities

FFR

Oil and Gas

Unique and differentiated product capabilities

Strong intellectual property with defined strategy to bring core products to market

Strong and committed management with proven track record

6

Diagnosis with FFR* = Guided PCI** Therapy

Aortic Pressure

Distal Pressure

Blockage

FFR = Distal Pressure

Aortic Pressure

FFR Ratio

Normal

Stent

* Fractional Flow Reserve ** Percutaneous Coronary Intervention

7

Attractive Industry Dynamics (FFR)

US$315B spent on coronary artery disease in the US

(AMA 2010 estimate)

Increasing Cost of

Coronary Artery

Disease

Attractive Market Dynamics Support FFR Industry Growth

US health care spending expected to grow by 5.8 to ~20%

of GDP by 2022 (CMS 2013 estimate)

FFR measurements facilitate reimbursement by hospitals

and third-party payers

Increasing Pressure

to Control Health

Care Costs

Patients and healthcare providers focused on reducing

invasive procedures to lower costs and improve standard

of care

Focus on Reducing

Invasive Procedures

8

Attractive Industry Dynamics (cont'd)

Year Milestones Outcome

2009 FAME I Study

Angiography + FFR +

Stent superior to

Angiography + Stent

2010

EU: ESC Class I

with Level of

Evidence A

Highest class and level

possible; procedure is

beneficial, useful and

effective

2011

US: ACC/AHA Class

IIA with Level of

Evidence A

Benefits of FFR

outweigh the risks and

it can be useful as a

tool

2012 FAME II Study

Angiography + FFR +

Stent + OMT superior to

Angiography + OMT

2012

(cont’d)

Japan: New

reimbursement

code for FFR

Code established

reimbursement for FFR

during diagnostic

angiography for the 1st

time

FFR Industry Milestones Key Takeaways

In recent years, landmark studies have

demonstrated clear clinical benefits to

using FFR

Facilitates invasive procedure decision-

making

Improves patient outcomes

Helps avoid unnecessary medical

procedures

Multiple cardiology medical societies

address the use of FFR in appropriate use

criteria for diagnostic evaluation

ESC has given FFR a Class I, Level A

recommendation, the highest possible

FFR market could grow significantly if

ACC/AHA increases recommendation

from Class IIA to Class I

Mgmt estimate 2013 FFR market: >US$250M

Current FFR penetration: ~14-15%Industry players indicate potential: 45%

Significant growth available from

Meeting unmet needs for cardiologistsIncreased penetrationFFR expansion into new indications and markets (peripherals)

Management expects FFR market growth to ~15-17% annually until 2017

Other players in FFR market have referenced market size to >US$1B

9

Attractive Industry Dynamics (cont'd)

Mgmt’s Estimated

Global Market Size (US$ M)

* Source: Research estimates and various company filings

Key Drivers

$57$75

$124

$167

$207

$250

$1,000 +

2008 2009 2010 2011 2012 2013 Beyond

10

Unique and Differentiated Product Capabilities (FFR)

OptoMonitor and OptoWire

Supported by 10 patents (8 granted, 2 pending)

Strong IP (Sensor, detection scheme, guidewire, connectivity of sensor

tools, medical application of technology)

11

Unique and Differentiated Product Capabilities (cont’d)

Opsens’ Patented Designs Provide Unique Capabilities

Torque TransferSensor Wires Optical Fiber

Conventional Pressure

Guidewire

Opsens Optical Pressure

Guidewire

12

OptoWire – Aiming to Fulfill Critical Unmet Needs

Conventional

Pressure Guidewire

* Source: Research estimates and various company filings

Opsens

Optical Pressure Guidewire

First nitinol-based optical pressure

guidewire – Construction similar to

non-pressure workhorse guidewires

known for kink-crush resistance,

superior pushability and torquability

Pressure system delivers high-fidelity,

reliability FFR assessment

Connectivity shows NO sensitivity to

contrast agents, allowing post-stent

and multi-vessels FFR assessment

Mechanical performance

Lesions difficult to reach

Delays in procedures

FFR assessment reliability

Pressure drift leads to

unreliable FFR assessment

Connectivity compatibility with PCI

ProcedureContrast agents prevent multiple

connection, hindering post-stent

and multi-vessels FFR assessment

13

Defined Strategy to Bring Core Products to Market

Commercialization

4Q13 1Q14 2Q14 3Q14 4Q14 2015

U.S.

E.U.

Japan

Design

Verification

& Validation

File 510(k) 510(k) Review

File for CE Marking

File PMDA

CE Review

PMDA Review

Commercial Launch

Commercial Launch

Commercial Launch

Commercial launch of OptoWire expected in 2015 with key milestone events

expected to be achieved in 2014

Japan: signed agreement with a medical distributor in Nov. 2012, providing the

Japanese Company with distribution rights in Japan, Korea and Taiwan;

Approval and commercial launch anticipated by end of 2014

US & EU: approval and commercial launch in early 2015

* Based on calendar year

14

Focused on Markets with Attractive Growth Opportunities (O&G)

Producers are shifting to unconventional oil

resources to meet demand

SAGD technology is primary technology used in oil

sands

In Canada, SAGD-based production has grown at

~12% annually since 2006

SAGD-based production is expected to grow at ~7%

over the next two decades

Opsens successfully completed adoption phase

O&G sensors have been in market for over 5

years

Sensor used by 4 of the top 10 SAGD producers

O&G sensors provide a recurring revenue stream

with high-margins

In some applications, sensors are replaced

every 18-30 months

Oil and Gas Market SAGD Production Forecast (1)

0

500

1000

1500

2000

2012 2016 2020

SAGD Production Forecast (bbl/day x 1,000)

(1) SAGD Instrumentation Market Assessment, Ian Murray & Company Ltd., Consultant report, June 26, 2012.

According to CAPP, SAGD production is expected

to grow at a rate of ~7% over next two decades

1515

Unique and Differentiated Product Capabilities

Steam Injection Well

Producing Well

Cold Oil Sand

Opsens’ OPP-W Sensor at pumpfor in-situ P/T monitoring (300ºC)

SRU Installation

Heated Oil

Hot Steam Chamber(200-300ºC +)

OPP-W at toe of well

16

Distribution impacts recovery rate along well pairs

Optimal Subcool zoneLow or Zero Subcool zone High Subcool zone

Unique and Differentiated Product Capabilities (cont’d)

Opsens’ fibre optic sensors offer improved temp and pressure measurements

at temp up to 300 C

Improve subcool for higher recovery rate

Improve subcool for better steam management

Subcool Zone Distribution - SOR

OPP-W in Injector and Producer Pipes

17

Growth Strategy

Gaining market share in expanding FFR markets

Expanding and investing in FFR-focused distribution channels and sales force

Developing new applications for the Company’s FFR technology

Increasing long-term revenues in the Oil and Gas market

Investing in innovation to enhance existing applications of the Company’s technology

18

Strong & Committed Management, Proven Track Record

Louis Laflamme, President & CEO – Involved with various high-tech public and

private companies

Thierry Dumas, CFO – Previously Corp. Controller for Atrium Innovations and

various positions at PricewaterhouseCoopers and Ernst & Young

Claude Belleville, VP Life Sciences – Successfully sold his first fibre optic venture

Gaétan Duplan, VP Oil & Gas – Successfully sold his first fibre optic venture

Scientific Advisory Board

Senior Management

Opsens’ senior management team fully committed with significant ownership stake

(~30%) in the Company

Opsens benefits from a scientific advisory board of cardiologists

Dr. Morton J. Kern – University of California, Irvine Cardiology, Chairman

Dr. Olivier F. Bertrand - Quebec Heart-Lung Institute, QC, Cardiologist

Dr. Michael J. Lim - St. Louis University, Cardiologist

19

Investment Highlights

Platform technology focused on markets with attractive growth opportunities

FFR

Oil and Gas

Unique and differentiated product capabilities

Strong intellectual property with defined strategy to bring core products to market

Strong and committed management with proven track record

20